Pulse Biosciences Cash Jumps in Q2
Pulse Biosciences (NASDAQ:PLSE), a medical device innovator focused on nanosecond pulsed field ablation (nsPFA) for treating various conditions, released its second-quarter 2025 results on August 12, 2025. The company reported another pre-commercial quarter, with no revenue. Operating expenses increased substantially amid ongoing clinical trial expansion and commercialization preparations. Cash and cash equivalents totaled $106.3 million as of June 30, 2025, up from $26.2 million a year earlier. Overall, the results show the company’s rapid advance through clinical and regulatory milestones while highlighting the sustained financial investment needed ahead of first product revenue.
Source: Analyst estimates for the quarter provided by FactSet.
Pulse Biosciences is developing the CellFX System, a device that uses ultrafast electrical pulses to treat unwanted or problematic tissue while sparing healthy cells. The underlying nsPFA technology is being tested for uses in soft tissue tumor removal, treatment of benign thyroid nodules, and cardiac ablation for atrial fibrillation (AF), a type of heart rhythm disorder.
Source Fool.com
Pulse Biosciences Inc Aktie
Noch keine eindeutige Richtung: Pulse Biosciences Inc mit zu wenigen Einschätzungen.
Das von der Community festgelegte Kursziel von 18 € für Pulse Biosciences Inc deutet auf ein leichtes Wachstumspotenzial im Vergleich zu 17.2 € hin.
